Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05047341
Other study ID # SHR0302-107
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 7, 2021
Est. completion date June 8, 2022

Study information

Verified date June 2022
Source Jiangsu HengRui Medicine Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is being conducted to evaluate the absorption, metabolism and excretion of [14C]SHR0302 in healthy Chinese adult male subjects.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date June 8, 2022
Est. primary completion date September 19, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Voluntarily sign the informed consent form, communicate well with the investigator and be able to complete the trial in strict compliance with the protocol; 2. Chinese male subjects judged by the investigator to be healthy; 3. Adults aged 18 to 45 years (including both ends of the spectrum, as at the time of signing the informed consent form); 4. Weight = 50 kg and a body mass index (BMI) in the range of 19 to 26 kg/m2 (both ends inclusive). Exclusion Criteria: Ancillary examinations : 1. Abnormalities in physical examination, vital signs, routine laboratory tests (complete blood cell analysis, blood biochemistry, coagulation, urine routine, stool routine + occult blood), thyroid function, 12-lead ECG, chest CT, abdominal ultrasound (liver, gallbladder, pancreas, spleen and kidney) and other tests of clinical significance. 2. Resting corrected QT interval (QTcF) >450 ms obtained on a 12-lead ECG. 3. Positive for hepatitis B surface antigen or E antigen, hepatitis C antibody, HIV antibody and syphilis antibody. 4. Screening for novel coronavirus infection with clinically significant abnormal C-reactive protein or positive novel coronavirus nucleic acid. Medication history: 5. Systemic use of any drug that inhibits or induces CYP3A within 30 days prior to the screening period (e.g., inducers - bosentan, paracetamol, efavirenz, etravirine, phenobarbital, rifampin, mitotane, phenytoin sodium, carbamazepine, apatamide, etc.; inhibitors - -erythromycin, clarithromycin, fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole, ciprofloxacin, diltiazem, fluvoxamine, nelfinavir, conivaptan, aripitant, crizotinib, imatinib, dronedarone, cyclosporine). 6. Have used any prescription drugs, over-the-counter medicines, herbal remedies or dietary supplements such as vitamins, calcium supplements within 14 days prior to the screening period. Medical and surgery history: 7. History of any clinically significant illness or disease or condition that, in the opinion of the investigator, may affect the results of the test, including but not limited to circulatory, respiratory, endocrine, neurological, digestive, urinary or haematological, immunological, psychiatric and metabolic disorders. 8. History of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmias, torsional ventricular tachycardia, ventricular tachycardia, atrioventricular block, QT prolongation syndrome or symptoms of QT prolongation syndrome and family history (indicated by genetic evidence or sudden death of a close relative at a young age due to cardiac causes). 9. Have undergone major surgery within the 6 months prior to the screening period or where the surgical incision has not fully healed; major surgery includes, but is not limited to, any surgery with significant risk of bleeding, extended general anaesthesia, or incisional biopsy or significant traumatic injury. 10. Allergies, such as a known history of allergy to two or more substances; or a potential allergy to the test drug or its excipients as judged by the investigator. 11. Haemorrhoids or perianal disease with regular/ongoing blood in the stool, irritable bowel syndrome, inflammatory bowel disease. Living habits: 12. Habitual constipation or diarrhoea. 13. Alcohol abuse or regular alcohol consumption within the 6 months prior to the screening period, i.e. more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits at 40% alcohol by volume or 150 mL of wine); or an alcohol breath test result of =20 mg/dL at the screening period. 14. Those who smoked more than 5 cigarettes per day or habitually used nicotine-containing products in the 3 months prior to the screening period and were unable to quit during the trial. 15. Substance abuse or use of soft drugs (e.g. cannabis) 3 months prior to the screening period or hard drugs (e.g. cocaine, amphetamines, phencyclidine, etc.) 1 year prior to the screening period; or a positive urine drug test during the screening period. 16. Habitual consumption of grapefruit juice or excessive amounts of tea, coffee and/or caffeinated beverages that cannot be abstained from during the trial. Others: 17. Workers exposed to prolonged radiological conditions; or who have had significant radiological exposure (=2 chest/abdominal CTs, or =3 other types of X-ray examinations) or participated in radiopharmaceutical labelling tests within 1 year prior to the test. 18. People who have a history of needle sickness or blood sickness, have difficulty collecting blood or cannot tolerate venipuncture blood collection. 19. Participation in any other clinical trial (including clinical trials such as drugs and devices) within 3 months prior to the screening period. 20. Those who have been vaccinated within 1 month prior to screening or those who are scheduled to be vaccinated during the trial period. 21. Those who plan to have children or donate sperm during the trial and within 1 year after completion of the trial, or who do not agree that subjects and their spouses should use strict contraception during the trial and within 1 year after completion of the trial (see Annex 1 for details). 22. Those who have lost or donated up to 400 mL of blood within 3 months prior to the screening period, or those who have received a blood transfusion within 1 month. 23. Subjects who, in the opinion of the investigator, have any factors that make them unsuitable for this trial.

Study Design


Intervention

Drug:
SHR0302?[14C]SHR0302
8 mg SHR0302/ 80 µCi [14C]SHR0302, once, D1

Locations

Country Name City State
China the first affiliated hospital of Soochow University Suzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax day 1 to day 11
Primary AUC0-t day 1 to day 11
Primary AUC0-8 day 1 to day 11
Primary Tmax day 1 to day 11
Primary t1/2 day 1 to day 11
Primary CL/F day 1 to day 11
Primary Vz/F day 1 to day 11
Secondary The incidence and severity of adverse events/serious adverse events from ICF signing date to approximate day 11
See also
  Status Clinical Trial Phase
Withdrawn NCT02786563 - Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
Completed NCT03257852 - A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate Phase 2
Completed NCT03660059 - A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) Phase 3
Recruiting NCT03971253 - Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
Not yet recruiting NCT05486715 - Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients
Completed NCT03682705 - A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis Phase 2
Active, not recruiting NCT04574492 - A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
Active, not recruiting NCT02805010 - Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously Phase 1
Completed NCT01871961 - Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient Phase 1
Completed NCT04497597 - A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Terminated NCT02775656 - UCB Cimzia Pregnancy Follow-up Study
Completed NCT01173120 - Methotrexate - Inadequate Response Device Sub-Study Phase 3
Completed NCT03223012 - Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
Completed NCT03086343 - A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs Phase 3
Terminated NCT01569152 - Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008) Phase 2
Completed NCT02105129 - A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523 Phase 1
Completed NCT01618955 - Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device Phase 2
Completed NCT01618968 - Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device Phase 2
Completed NCT01577563 - Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). N/A
Completed NCT03339089 - Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases